iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, announces that it has secured regulatory approval for its SecondLook® Digital by the State Food and Drug Administration (SFDA) in the People’s Republic of China. The approval allows iCAD’s SecondLook Digital computer-aided detection (CAD) technology to be sold with GE Digital Mammography Systems in order to assist radiologists in distinguishing potential cancers from other anomalies on a mammogram.
